Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Unicycive Therapeutics and keeping the price target at $30.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jason McCarthy has given his Buy rating due to a combination of factors influencing Unicycive Therapeutics’ potential. The company is making progress in addressing the FDA’s complete response letter for its oxylanthanum carbonate (OLC) treatment, with expectations to resubmit the NDA by the end of the year. This resubmission could lead to a new PDUFA date in the first half of 2026, which is a significant milestone for the company.
Additionally, the Phase 2 study of OLC has shown promising results, including improved patient adherence and satisfaction compared to previous treatments. The innovative nanoparticle formulation of OLC reduces pill burden and enhances patient experience, which could support its market adoption. Although commercialization estimates have been adjusted to the second half of 2026, the company is positioned to benefit from the TDAPA period, potentially accelerating market traction. These factors, along with a strategic valuation approach, underpin the Buy rating.
In another report released on November 13, H.C. Wainwright also maintained a Buy rating on the stock with a $22.00 price target.